H.C. Wainwright Lifts PT on BioCryst Pharmaceuticals (BCRX) to $32 From $30

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) is one of the best small cap stocks to buy with huge upside potential. H.C. Wainwright lifted the price target on BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) to $32 from $30 on December 15, and reaffirmed a Buy rating on the stock. The firm told investors that the approval of Orladeyo in the pediatric patient population marks a significant factor for the rating update, as Orladeyo is the first and only targeted oral prophylactic therapy approved for use in patients ages two to 12 with hereditary angioedema.

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) announced on December 12 that the FDA approved its New Drug Application (NDA) for the use of an oral pellet formulation of once-daily ORLADEYO (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema aged 2 to <12 years. The only targeted treatment options for patients under age 12, until now, were administered either intravenously or through subcutaneous injection, which could prove burdensome for younger patients and their caregivers.

Management further reported that the FDA granted approval to a capsule formulation of ORLADEYO for prophylaxis for the prevention of HAE attacks in adult and pediatric patients 12 years and older in December 2020, which now holds approval in over 45 countries across the globe.

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) is a biotechnology company that provides structure-guided drug design to develop oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.